BIO 2026: Biopharma Dealmakers Seek to Protect ‘Premium Pricing’ From Trump’s MFN Policy

Why It Matters

The MFN rule threatens U.S. premium pricing, compelling firms to redesign global launch strategies and contract structures, which could ripple through investment flows and patient access worldwide.

Key Takeaways

• Trump’s MFN policy forces U.S. drug prices to match high‑income peers
• Big pharma may skip European launches to preserve premium U.S. pricing
• Deal terms now require flexibility for ex‑U.S. rights or renegotiation
• Legal teams cite uncertainty, adding arbitration and renegotiation clauses
• Orphan, cell and gene therapies may qualify for MFN exemptions

Pulse Analysis

The Trump administration’s Most Favored Nation (MFN) pricing framework represents a dramatic shift in how biopharma companies price U.S. drugs. By tying American prices to those in peer economies such as Germany and the United Kingdom, the policy aims to curb perceived excesses but also erodes the traditional premium that U.S. markets have commanded. Industry leaders view the rule as a catalyst for re‑evaluating global launch sequences, with many now considering a U.S.-first approach to safeguard revenue streams.

This pricing pressure is reverberating through dealmaking circles at BIO 2026. Executives from Bayer, United Therapeutics, and other majors disclosed that future licensing and M&A agreements will need explicit flexibility for relinquishing ex‑U.S. rights or embedding renegotiation triggers. Legal counsel, traditionally averse to “dirty‑word” renegotiation clauses, is now drafting arbitration provisions to manage policy‑related risk. The uncertainty hampers financial modeling, as firms struggle to quantify the impact of an undefined regulatory environment on deal valuations.

Patient access and market dynamics remain the ultimate stakes. While certain orphan drugs, cell therapies, and antibody‑drug conjugates may qualify for MFN exemptions, the broader cohort faces delayed or abandoned launches in Europe, potentially limiting treatment options abroad. Investors are watching closely, as the policy could reshape capital allocation toward U.S.-centric pipelines. The industry’s response—whether through strategic pricing, contractual innovation, or lobbying for policy adjustments—will define the next wave of biopharma growth and global health outcomes.